COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study of an Extended Release (ER) Tablet, Single and Repeated Dosing

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00689039
Recruitment Status : Completed
First Posted : June 3, 2008
Last Update Posted : December 3, 2010
Information provided by:

Brief Summary:
The purpose is to study the safety and tolerability of increasing doses of AZD1305 and how the medication is metabolised by the body (how it is taken up, distributed, and how it disappears from the body). The study is performed in healthy volunteers.

Condition or disease Intervention/treatment Phase
Healthy Drug: AZD1305 Drug: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 94 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: A Two-part, Single-centre, Open (Part A) Single Blind (Part B), Randomised, Placebo-controlled Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics After Single Doses With and Without Food and Multiple Ascending Oral Doses of AZD1305 Extended-release Tablet in Healthy & Elderly Subj
Study Start Date : April 2007
Actual Primary Completion Date : July 2008
Actual Study Completion Date : July 2008

Arm Intervention/treatment
Experimental: A
AZD1305 ER tablet
Drug: AZD1305
ER tablet, administered as single and repeated doses.

Placebo Comparator: B
Placebo tablet
Drug: Placebo
Tablet, administered as single and repeated doses.

Primary Outcome Measures :
  1. Adverse events, ECG, vital signs, physical examination, laboratory variables, body temperature and weight [ Time Frame: During the study ]

Secondary Outcome Measures :
  1. Pharmacokinetic variables [ Time Frame: During all dosing visits ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • A body mass index (BMI=weight/height2) of 19 to 27 kg/m2
  • Clinically normal physical findings, laboratory values and resting ECG as judged by the investigator

Exclusion Criteria:

  • ECG findings outside normal range
  • Potassium outside normal reference values

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00689039

Layout table for location information
Research Site
Göteborg, Sweden
Sponsors and Collaborators
Layout table for investigator information
Study Director: Helen Lunde, MD AstraZeneca R&D Mölndal, Sweden
Principal Investigator: Marianne Hartford, MD, PhD AstraZeneca, Clinical Pharmacology Unit at Sahlgrenska University Hospital, Sweden

Layout table for additonal information
Responsible Party: Helen Lunde, MD, Medical Science Director, Emerging Arrhythmia and Lipids, AstraZeneca Identifier: NCT00689039    
Other Study ID Numbers: D3190C00004
2006-006356-35 (EudraCT No)
First Posted: June 3, 2008    Key Record Dates
Last Update Posted: December 3, 2010
Last Verified: December 2010
Keywords provided by AstraZeneca:
multiple ascending doses
Safety and pharmacokinetics